Pain is a serious, physically debilitating condition that represents an enormous public health problem. It affects productivity, mood, social life and daily activities, can cause insomnia and is often accompanied by emotional distress, anxiety and depression. Moreover, it negatively impacts the well-being of family members.
Angelini has a long tradition of research in pain and inflammation. Its R&D is focused not only on the identification of new active principles, but also on the study of known substances to improve their clinical efficacy and positively impact patient outcomes.
The development of novel formulations with increased efficacy and a better safety profile, also addressing patient compliance and convenience, is part of our continuous effort through excellence and concrete results.
Angelini has a holistic approach that goes beyond the pill: our mission is to improve patient management, taking the whole person into consideration, with his/her physical, emotional and mental aspects. Therefore, solutions are not limited to pain control, but are directed to preserve dignity, relational abilities and full social integration.
BTcP has a negative impact on general activities and pain management in oncological patients.
Chronic pain – a complex phenomenon – can cause emotional distress which can negatively impact on biological and behavioural reactions, that, in turn, may adversely affect the patient’s mood.
Breakthrough cancer pain (BTcP) is a common condition that occurs in oncological patients. Currently, there is no universally accepted definition of BTcP and, therefore, standardized diagnostic criteria lack.